



Sci

Indexed in:
Scopus

an Open Access Journal by MDPI

Development of Targeted Therapies for the Clinical Management of Cancer

Guest Editor:

Dr. Mark Brown

1. Department of Clinical Sciences, Colorado State University, Fort Collins, CO 80523, USA
2. Epidemiology Section, Colorado School of Public Health, Fort Collins, CO 80523, USA
3. Cell and Molecular Biology Program, Colorado State University, Fort Collins, CO 80523, USA

mark.brown@colostate.edu

Message from the Guest Editor

Dear Colleagues,

The development of targeted therapeutics has revolutionized the approach to targeting cancer in a way that minimizes the adverse side-effects associated with broad-spectrum applications. For example, small molecule enzyme inhibitors and monoclonal antibodies can be designed to target the specific biomolecules involved in tumorigenic cascades. In this Special Issue of *Sci*, we invite papers related to the design, development, testing, and regulatory approval pathways associated with targeted oncology therapeutics.

Deadline for manuscript submissions:

closed (15 October 2020)



mdpi.com/si/38920

Special Issue